-
公开(公告)号：US11040059B2
公开(公告)日：2021-06-22
申请号：US15522466
申请日：2015-10-27
IPC分类号： A61K31/721 , A61K47/10 , A61K9/00 , A61K31/295
摘要： The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.
-
公开(公告)号：US11471483B2
公开(公告)日：2022-10-18
申请号：US17182366
申请日：2021-02-23
摘要： The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, or pallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.
-
公开(公告)号：US11040064B2
公开(公告)日：2021-06-22
申请号：US15554762
申请日：2016-03-17
摘要： The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, orpallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.
-
公开(公告)号：US10960081B2
公开(公告)日：2021-03-30
申请号：US15572382
申请日：2016-06-22
IPC分类号： A61K31/706 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K47/61 , A61K33/26 , A61P3/02
摘要： Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
-
公开(公告)号：US11806329B2
公开(公告)日：2023-11-07
申请号：US17187992
申请日：2021-03-01
发明人： Tobias Sidelmann Christensen , Philip Schaffalitzky De Muckadell , Lars Lykke Thomsen , Claes Christian Strom
IPC分类号： A61K31/7016 , A61P7/06 , A61P43/00 , A61K31/295
CPC分类号： A61K31/295 , A61P7/06
摘要： The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.
-
公开(公告)号：US11633489B2
公开(公告)日：2023-04-25
申请号：US17178430
申请日：2021-02-18
摘要： Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
-
公开(公告)号：US11020369B2
公开(公告)日：2021-06-01
申请号：US16822911
申请日：2020-03-18
发明人： Tobias Sidelmann Christensen , Philip Schaffalitzky De Muckadell , Lars Lykke Thomsen , Claes Christian Strom
IPC分类号： A61K31/7016 , A61P7/06 , A61P43/00 , A61K31/295
摘要： The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
